PropThink’s Weekly Roundup
Most Popular - The event of the week? Phase III data for Zerenex, Keryx Biopharmaceutical’s phosphate binder, were released on Monday, with compelling results. PropThink has been covering … Continue Reading
Read nowSearch Results for keryx
Game-Changing Zerenex Results, More Than 1 Year In Cash; KERX To Trade Higher
Long Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) has been a booming success for PropThink, with the stock doubling since PropThink first got behind the Zerenex data in mid-October. And, our … Continue Reading
Read nowPropThink’s Healthcare Week-in-Review
Long Ideas - The highlight of our week was Allergan’s ~$1B buyout of MAP Pharmaceuticals, a company that we recommended in early January. The acquisition came at a … Continue Reading
Read nowZerenex Phase III Data Imminent; Still High Odds for KERX To Succeed With This Drug
Long Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) miscalculated the timing for when its CRO (contract research organization) would deliver Phase III results for Zerenex, the company’s phosphate-binder candidate for … Continue Reading
Read nowPropThink’s End-of-Week Recap
Most Popular - We spent the week in San Francisco for the JP Morgan and Biotech Showcase conferences, which proved invaluable for idea generation, networking, and the solidifying of some … Continue Reading
Read nowKERX Has a Drug; Partner Files For Zerenex Approval In Japan
Long Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced Monday morning that its Japanese development partner JT Tori Pharmaceutical Co. submitted a new drug application (NDA) for Zerenex, the company’s … Continue Reading
Read nowPropThink’s Weekly Healthcare Recap
Most Popular - A catalyst-rich 2013 and a solid financial position for BioMarin should push the stock higher. Since we published this story on Monday, shares of the drug … Continue Reading
Read now